Five Prime Therapeutics (FPRX) Cut to “Sell” at BidaskClub

BidaskClub lowered shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a sell rating in a research note issued to investors on Monday morning.

A number of other equities research analysts have also issued reports on the company. BMO Capital Markets increased their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an outperform rating in a research note on Tuesday, November 7th. Royal Bank of Canada reissued a buy rating and issued a $41.00 price target on shares of Five Prime Therapeutics in a report on Wednesday, October 25th. Zacks Investment Research downgraded Five Prime Therapeutics from a buy rating to a hold rating in a report on Thursday, November 9th. Finally, ValuEngine downgraded Five Prime Therapeutics from a hold rating to a sell rating in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $64.00.

Shares of Five Prime Therapeutics (NASDAQ FPRX) opened at $18.42 on Monday. Five Prime Therapeutics has a 12 month low of $18.41 and a 12 month high of $49.30. The stock has a market capitalization of $647.90, a PE ratio of -3.64 and a beta of 3.56.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The company had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. During the same quarter last year, the business posted ($0.72) EPS. Five Prime Therapeutics’s quarterly revenue was up 24.7% compared to the same quarter last year. research analysts expect that Five Prime Therapeutics will post -5.56 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. bought a new position in Five Prime Therapeutics during the 3rd quarter worth approximately $223,000. Dupont Capital Management Corp bought a new position in Five Prime Therapeutics during the 3rd quarter worth approximately $341,000. Legal & General Group Plc lifted its holdings in Five Prime Therapeutics by 3.1% during the 2nd quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 287 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Five Prime Therapeutics during the 2nd quarter worth approximately $331,000. Finally, Tudor Investment Corp ET AL lifted its holdings in Five Prime Therapeutics by 49.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock worth $361,000 after buying an additional 3,966 shares during the last quarter. 71.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Five Prime Therapeutics (FPRX) Cut to “Sell” at BidaskClub” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/06/five-prime-therapeutics-fprx-cut-to-sell-at-bidaskclub.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit